J. I. D. Mingorance

Most-cited papers

1. Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.

   A. Brufsky, Sung-Bae Kim, T. Velu, J. G. Sáenz +15 more

   20167 citations

   Semantic Scholar

   Save

2. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study.

   Jaime Feliú Batlle, Mónica Jorge Fernández, T. Macarulla, B. Massutí +13 more

   2020Journal of Clinical Oncology4 citations

   Semantic Scholar

   Save

3. Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.

   D. Juric, S. Loibl, F. André, J. I. D. Mingorance +12 more

   2019Journal of Clinical Oncology3 citations

   Semantic Scholar

   Save

4. Abstract PS5-01-30: Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): Final analysis from DESTINY-Breast03

   S. Im, J. Cortes, S.-B. Kim, G. Curigliano +14 more

   2026Clinical Cancer Research0 citations

   Semantic Scholar

   Save

5. Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).

   L. Manso, F. Moreno, J. I. D. Mingorance, M. Echarri +10 more

   20150 citations

   Semantic Scholar

   Save